Format

Send to

Choose Destination
Exp Mol Med. 2009 Feb 28;41(2):61-6.

Improving vaccines by targeting antigens to dendritic cells.

Author information

1
The Walter and Eliza Hall Institute of Medical Research, Parkville Victoria 3050, Australia. shortman@wehi.edu.au

Abstract

A new approach to enhancing the effectiveness of vaccines is to deliver antigens selectively to dendritic cells (DC) in situ, via monoclonal antibodies specific for particular DC surface molecules. This can markedly enhance CTL responses and, via helper T cells, also enhance antibody responses. DC activation agents or adjuvants must also be administered for effective CTL responses, but in some cases good antibody responses can be obtained without adjuvants. Here we review the role of different DC subsets and different DC target molecules in obtaining enhanced immune responses.

PMID:
19287186
PMCID:
PMC2679330
DOI:
10.3858/emm.2009.41.2.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center